Quarterly report pursuant to Section 13 or 15(d)

Schedule of Accounts Payable to Related Party (Details)

v3.24.3
Schedule of Accounts Payable to Related Party (Details) - Cytovance Biologics Inc [Member] - USD ($)
9 Months Ended
Sep. 30, 2024
Sep. 30, 2023
Defined Benefit Plan Disclosure [Line Items]    
Beginning balance $ 3,515,000 [1] $ 2,283,000
Invoices, net 1,365,000 3,691,000
Payments in cash (3,432,000) (1,710,000)
Payments in common stock, at fair value (810,000) (1,120,000)
Ending balance $ 638,000 [1] $ 3,144,000
[1] Accounts Payable to Cytovance Biologics, Inc. (“Cytovance”), a Related Party, since Cytovance owns greater than 5% of the Company’s issued and outstanding common stock